| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| ABVC BioPharma Inc. | ABV-1703 | Pancreatic Cancer | Phase 2 | IND Clearance | Intravenous | Oncology |
| ABVC BioPharma Inc. | ABV-1501 | Triple Negative Breast Cancer (TNBC) | Phase 2 | IND Clearance | Intravenous | Oncology |
| ABVC BioPharma Inc. | ABV-1504 | Major Depressive Disorder (MDD) | Phase 2 | Trial Completed | Oral | Psychiatric |
| ABVC BioPharma Inc. | ABV-1504 | Major Depressive Disorder (MDD) | Phase 2 | Trial Completed | Oral | Psychiatric |
| ABVC BioPharma Inc. | Vitargus - (ABV-1701) | Ocular Endotamponade (OE) | Phase 2 | Trial Discontinued | Intravitreal | Opthalmic |
| ABVC BioPharma Inc. | PDC-1421 | Attention-Deficit Hyperactivity Disorder (ADHD) | Phase 2 | Trial Completed | Oral | Psychiatric |
| ABVC BioPharma Inc. | Vitrargus - (Australia trial) | Retinal detachment | Phase 2 | Trial Planned | Intravitreal injection | Opthalmic |
| ABVC BioPharma Inc. | ABV-1505 | Attention Deficit Hyperactivity Disorder (ADHD) | Phase 2a | Enrollment Conclusion | Oral | Psychiatric |